Miravo Healthcare™ and Searchlight Pharma Inc. Announce Closing of Arrangement
Miravo Healthcare™ Obtains Final Order Approving Plan of Arrangement
Miravo Healthcare™ Announces Shareholder Approval of Plan of Arrangement
Miravo Healthcare™ Special Meeting Reminder
Miravo Healthcare™ Announces Filing of Special Meeting Materials in respect of Arrangement with Searchlight Pharma Inc.
Nuvo Pharmaceuticals d/b/a Miravo Healthcare and Searchlight Pharma, a private Canadian-based specialty healthcare company have entered into a definitive agreement pursuant to which the Purchaser has agreed to acquire all of the issued and outstanding common shares of the company in exchange for cash consideration of $1.35 per Company Share, representing a 79.8% premium to the 90-day volume-weighted average trading price of the company Shares on the Toronto Stock Exchange for the period ended December 22, 2022.
Miravo Healthcare™ Announces Third Quarter 2022 Results
MISSISSAUGA, Ontario,--(BUSINESS WIRE)--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its third quarter 2022 financial results before markets open on Monday, November 14, 2022.
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced the appointment of Anthony Snow to its Board of Directors (Board) on August 12, 2022.
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its second quarter 2022 financial results before markets open on Monday, August 15, 2022.